Adiponectin
Adiponectin (ADIPOQ)
Written by Aaron CuhaReviewed Sep 2026
Also known as: ADIPOQ
The fat hormone that falls as fat mass rises, and the source of a large observational literature. It has never been given to a human, Mendelian randomisation in up to 80,000 people does not support the idea that low adiponectin causes insulin resistance or diabetes, and in older adults higher levels predict higher mortality.
Overview
Adiponectin is a 226 amino acid protein secreted by fat cells that circulates at unusually high concentrations as trimers, hexamers and high molecular weight multimers. Unlike almost every other adipokine, its level falls as fat mass rises, and low adiponectin is strongly correlated with insulin resistance, type 2 diabetes and cardiovascular disease in cross-sectional and cohort studies. That correlation is the entire basis of the popular claim that adiponectin is the good adipokine and that raising it would help.
Recombinant adiponectin has never been given to a human in any trial we could find, no adiponectin drug exists, and no adiponectin receptor agonist has entered human testing; a PubMed search for human trials of the research compound AdipoRon returned nothing on 11 September 2026. So the human evidence is entirely observational and genetic, and the genetic evidence cuts against the causal story. A 2013 Mendelian randomisation analysis used variants at the ADIPOQ gene as instruments in up to 31,000 people for metabolic traits, 2,969 with gold-standard insulin sensitivity measures and 15,960 diabetes cases against 64,731 controls. In ordinary regression, one standard deviation lower adiponectin went with a 1.75-fold odds of diabetes. Genetically lower adiponectin went with no increase in fasting insulin (0.02 SD), no increase in diabetes risk (odds ratio 0.94, 95 percent CI 0.75 to 1.19), and at best nominal evidence on insulin sensitivity that did not hold with the second method. The authors concluded there was no consistent evidence that raising adiponectin would improve insulin sensitivity or diabetes risk.
The mortality data point the wrong way for a protective hormone. In the Cardiovascular Health Study of older adults, the association of adiponectin with all-cause death was U-shaped in people free of cardiovascular disease (lower risk up to 12.4 mg/L, hazard ratio 0.81 per SD below that, then 1.19 per SD above it), flat in those with cardiovascular disease, and directly harmful in those with heart failure or atrial fibrillation (hazard ratio 1.31 per SD after adjustment). A Mendelian randomisation analysis in 356 patients with type 2 diabetes found the genetic instrument for higher adiponectin predicted higher cardiovascular mortality (incidence rate ratio 1.94), suggesting the adiponectin paradox is causal rather than confounded. Whether this reflects a compensatory rise, resistance to adiponectin, or a direct harmful action is disputed in the literature and we present it as disputed.
Everything therapeutic is in mice: the receptor cloning in 2003, and AdipoRon, an oral small molecule that activates both receptors, improves glucose handling in diet-induced obese mice and extends the shortened lifespan of db/db mice on a high-fat diet. AdipoRon is sold as a research chemical with no human safety data.
Mechanism of action
Established in mice and in vitro: adiponectin binds AdipoR1 and AdipoR2, seven-transmembrane receptors with the opposite orientation to G protein-coupled receptors, and T-cadherin. AdipoR1 signals mainly through AMPK and AdipoR2 through PPAR-alpha, increasing fatty acid oxidation in muscle and liver and improving insulin sensitivity; the high molecular weight multimer is the form most often reported as active. AdipoRon reproduces these effects in mice and its action is abolished in double receptor knockouts. In humans: adiponectin is inversely correlated with fat mass, insulin resistance and diabetes, but genetic evidence does not support a causal effect of adiponectin level on insulin sensitivity or diabetes, and in older adults and people with cardiovascular disease higher adiponectin predicts higher mortality. No mechanism has been established in a person because no one has changed adiponectin in a person to see what happens.
Human evidence
No human has received adiponectin or an adiponectin receptor agonist in any trial we could find. The human record is observational association and Mendelian randomisation, and the genetics do not support the causal story the observational data suggested.
- Mendelian randomisation (Diabetes 2013): up to 31,000 for metabolic traits, 2,969 with clamp-grade insulin sensitivity, 15,960 diabetes cases and 64,731 controls. Genetically lower adiponectin was not associated with higher fasting insulin or with diabetes (OR 0.94).
- Cardiovascular Health Study (Circulation 2012), older adults: U-shaped mortality association without cardiovascular disease (harm above 12.4 mg/L, HR 1.19 per SD), direct harm with heart failure or atrial fibrillation (HR 1.31 per SD).
- Gargano Heart Study (Cardiovasc Diabetol 2016): 356 people with type 2 diabetes, genetic instrument for higher adiponectin predicted cardiovascular death (IRR 1.94).
- PubMed, searched 11 September 2026: no human clinical trial of AdipoRon. ClinicalTrials.gov: no interventional trial of recombinant adiponectin or AdipoRon.
What this does not tell you: Association studies cannot tell you what raising or lowering adiponectin would do, and the genetic studies that come closest say that for insulin resistance and diabetes it would do nothing detectable. The mortality paradox is consistent across older and cardiac cohorts but its explanation is contested: a compensatory rise in the sick, resistance to the hormone, or a direct harmful effect would each produce the same curve. None of the human data bears on adiponectin supplementation because there is no such thing, and none bears on AdipoRon because it has never been given to a person. Anyone using AdipoRon is the first human safety study of it.
Reading the research record
Adiponectin is the clearest case on this site of an observational literature that outran its causal support. Hundreds of papers report that low adiponectin accompanies obesity, insulin resistance, diabetes and heart disease, and the 2003 receptor cloning gave the correlation a mechanism in mice. The natural conclusion, that adiponectin protects and raising it would help, is what most peptide and supplement pages state. The 2013 Mendelian randomisation study, from a large NIH-funded consortium, tested that conclusion with genetics in tens of thousands of people and could not support it: alleles that lower adiponectin do not raise diabetes risk. The point is not that adiponectin does nothing, but that its level is a consequence of metabolic state at least as much as a cause of it, and that interventions to raise it have no human rationale.
The mortality paradox is the other half of the correction, and it is a genuine dispute. In the Cardiovascular Health Study higher adiponectin predicted death in older adults with cardiovascular dysfunction, and one small Italian genetic study argues the effect is causal. The competing explanation, that the failing heart releases natriuretic peptides which drive adiponectin up as a marker of severity, is argued in the reviews we cite, and a 2020 review questions whether the paradox even holds in stable coronary disease. We present the sides and do not choose. What is not in dispute is the absence of intervention data: no company has an adiponectin drug, the receptor agonist AdipoRon has been in mice since 2013 without a registered human trial, and the mouse lifespan extension it produced was the rescue of a shortened lifespan in a diabetic strain on a high-fat diet, not extension in normal animals. Anyone selling AdipoRon on an adiponectin rationale is extrapolating from mice across a gap that the human genetics specifically question.
The evidence, charted
Fig. 1 · evidence composition
3of 9 citations (33%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 6 distinct years, 2003 to 2020, counted from the citation list on this page. The newest citation on file is from 2020, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2013
Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes
ADIPOQ variants as instruments in up to 31,000 people, 2,969 with gold-standard insulin sensitivity, 15,960 diabetes cases and 64,731 controls. Observationally, 1 SD lower adiponectin went with 0.31 SD higher fasting insulin and diabetes odds of 1.75. Genetically lower adiponectin showed no association with fasting insulin (0.02 SD, 95 percent CI -0.07 to 0.11) or diabetes (OR 0.94, 0.75 to 1.19; genetic risk score OR 0.99 per allele). The authors found no consistent evidence that raising adiponectin would improve insulin sensitivity or diabetes risk. NIH funded.
Diabetes - Human2012
Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study
Population-based cohort of older adults. In those free of cardiovascular disease, the association with all-cause mortality was U-shaped: hazard ratio 0.81 per SD up to 12.4 mg/L, then 1.19 per SD (95 percent CI 1.12 to 1.27) above it. No association in those with cardiovascular disease alone; in heart failure or atrial fibrillation, higher adiponectin meant higher mortality, hazard ratio 1.31 (1.15 to 1.50) after adjustment. Results were similar for high molecular weight adiponectin and cardiovascular death. NIH funded.
Circulation - Human2016
Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes
Gargano Heart Study, 356 patients with type 2 diabetes, mean follow-up 5.4 years, 58 cardiovascular deaths. The ADIPOQ variant rs822354 raised adiponectin and was associated with cardiovascular mortality (incidence rate ratio 1.94, 95 percent CI 1.23 to 3.07), with a genetic effect larger than the observational one, interpreted by the authors as evidence that the paradoxical association is causal. Non-US government funded.
Cardiovascular Diabetology - Review2020
Is There Really an Association of High Circulating Adiponectin Concentration and Mortality or Morbidity Risk in Stable Coronary Artery Disease?
Review questioning how robust the adiponectin mortality paradox is in stable coronary disease and what confounding it might reflect; one side of a live dispute.
Hormone and Metabolic Research - Review2020
Insights Into the Controversial Aspects of Adiponectin in Cardiometabolic Disorders
Review setting out the competing explanations for high adiponectin predicting harm: compensatory secretion, adiponectin resistance, natriuretic peptide driven release in heart failure, or direct effects. Does not resolve them.
Hormone and Metabolic Research - Animal2003
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Identification of AdipoR1 and AdipoR2 and demonstration in mouse cells and tissues that they mediate adiponectin's effects on fatty acid oxidation and glucose uptake through AMPK and PPAR-alpha.
Nature - Review2005
Adiponectin and adiponectin receptors
Foundational review of adiponectin biology, multimer forms, receptors and the observational human associations, written before the Mendelian randomisation and mortality paradox data.
Endocrine Reviews - Animal2013
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
AdipoRon, an oral small molecule binding AdipoR1 and AdipoR2, activated AMPK and PPAR-alpha, improved insulin resistance and glucose tolerance in mice on a high-fat diet (abolished in double knockouts), ameliorated diabetes in db/db mice and prolonged their shortened lifespan on a high-fat diet. Mouse only; no human data exist.
Nature - Review2013
Adiponectin receptor as a key player in healthy longevity and obesity-related diseases
Review from the AdipoRon group framing adiponectin receptor agonism as a longevity strategy, on the strength of mouse and calorie restriction data.
Cell Metabolism
Frequently asked questions
Is low adiponectin the cause of insulin resistance?
It accompanies it, strongly: one standard deviation lower adiponectin goes with 1.75-fold odds of diabetes in observational data. But Mendelian randomisation in up to 80,000 people found that genetically lower adiponectin did not raise fasting insulin or diabetes risk (odds ratio 0.94). The genetic evidence does not support a causal role, and the authors concluded raising adiponectin would not be expected to help.
Is high adiponectin good?
Not straightforwardly. In older adults free of heart disease the relationship with death was U-shaped, with higher risk above about 12.4 mg/L. In people with heart failure or atrial fibrillation, higher adiponectin predicted higher mortality (hazard ratio 1.31 per standard deviation). Whether that is a marker of illness or a cause is disputed and unresolved.
Can I take adiponectin or AdipoRon?
No adiponectin product exists and recombinant adiponectin has never been given to a human. AdipoRon, the oral receptor agonist, has been studied only in mice since 2013; there is no registered human trial and no human safety data. It is sold as a research chemical.
Does adiponectin extend lifespan?
AdipoRon prolonged the shortened lifespan of diabetic db/db mice on a high-fat diet. That is a rescue in a sick strain, not lifespan extension in normal animals, and there is no human longevity data. In older humans, higher adiponectin predicts shorter survival.